Welcome to
STAb Therapeutics

About Us

Welcome to STAb Therapeutics

STAb Therapeutics is a spin-off company from the Research Institute Hospital 12 de Octubre (imas12), which focuses on developing next-generation immune redirection strategies for solid and hematological tumors. The company’s strategy involves a T cell redirecting approach that combines principles of adoptive cell therapy and bispecific antibodies. This approach is based on the in vivo production of T cell-engagers (TCE) by engineered cells, which results in effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb – T cells, and polyclonal recruitment of both modified and unmodified bystander T cells present at the tumor microenvironment.

Our Lab Certification

Our Company

Lorem mauris tincidunt lacus, id rhoncus erat facilisis purus sed consectetur in.

Learn More

Strategy

Nibh euismod massa ultrices sagittis, a tortor fermentum pulvinar interdum et ut.

Learn More

Our Location

Office: C/Calle Ferraz 78, 2º A, 28008 Madrid, Spain

Get Directions

Make An Appointment

Urna aliquet feugiat odio enim ut pharetra pretium velit viverra elementum pulvinar viverra diam urna rhoncus eu, et, malesuada luctus neque mollis morbi placerat.

Start Now

Book an appoitnment

+1 123 444 5678

Strategy

STAb immunotherapy is a T cell redirecting strategy that combines principles of adoptive cell therapy and bispecific antibodies, and is based on the in vivo production of T cell -engagers (TCE) by engineered cells. Sustained in vivo secretion results in effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb – T cells, and polyclonal recruitment of both modified and unmodified bystander T cells present at the tumor microenvironment, leading to significantly enhanced antitumor responses. Indeed, the therapeutic potential of STAb -T cells has been preclinically validated in B-cell and T cell hematological malignancies 

Strategy

STAb immunotherapy is a T cell redirecting strategy that combines principles of adoptive cell therapy and bispecific antibodies, and is based on the in vivo production of T cell -engagers (TCE) by engineered cells. Sustained in vivo secretion results in effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb – T cells, and polyclonal recruitment of both modified and unmodified bystander T cells present at the tumor microenvironment, leading to significantly enhanced antitumor responses. Indeed, the therapeutic potential of STAb -T cells has been preclinically validated in B-cell and T cell hematological malignancies 

4.7
of 5
4.7/5

4.8/5

1860 Reviews

4.6/5

1630 Reviews

4.7/5

2100 Reviews

News

STAb Therapeutics awarded by the Fundación para el Conocimiento Madri+d

STAb Therapeutics, spin-off from Instituto de Investigación Hospital 12 de Octubre i+12, has been awarded by the Fundación para el Conocimiento madri+d, in the framework of the health entrepreneurship program ‘Healthstart’.

STAb Therapeutics granted by Consejería de Educación, Ciencia y Universidades

STAb Therapeutics has been awarded with one of grants for the development of new innovative technology-based companies: “Ayudas para el desarrollo de nuevas empresas innovadoras de base tecnológica (start-up) (2023)”.

STAb Therapeutics appoints Carolina Pola as Chief Executive Officer

Dr. Pola brings a biobusiness perspective and expertise to STAb Therapeutics to develop and deploy the strategic plan for the growth of the Company.

She has developed an extensive investor and biotech network within Spain and abroad.

Pipeline

STAb-19: B-cell malignancies constitute a heterogeneous group of cancers that include B-cell leukemias and lymphomas. Among the acute lymphoblastic leukemias (ALL), B-cell ALL is the most common subtype, constituting approximately 85% of childhood ALL cases and 75% of adult ALL cases. B-cell lymphomas account for approximately 85% of all lymphomas. Although these malignancies constitute a very heterogeneous group of diseases, with different treatments and prognoses, in some of these pathologies the cure rate does not exceed 50-60% of patients. STAb-T19 is a cellular cancer immunotherapy developed as a treatment for patients with relapsed or refractory CD19-positive B-cell malignancies. It will enter clinical trials in early 2024.

Team

Carolina Pola

Chief Executive Officer

Belén Blanco

Chief Scientific Officer

Scientific Advisory Board

Luis Álvarez-Vallina

Joaquín Martínez

Luis Paz-Ares

Richard G. Vile

With the support of

The project “Evaluation of the safety of STAb-T19 cells in patients with B-cell hematological malignancies” was carried out in 2024 under the 2023 Call for Grants for the Development of Innovative Technology-Based Start-ups, funded by the Community of Madrid and the European Regional Development Fund (FEDER).


The main objective of this project is to develop the necessary studies to evaluate the safety of STAb-T19 cells in patients with B-cell hematological malignancies, and subsequently to conduct further studies to demonstrate the therapeutic efficacy of this approach.


To achieve this, the project included the planning and management of R&D activities aimed at IND-enabling validation of the therapy through in vitro and in vivo studies. The results obtained are paving the way for the clinical development of STAb-T19, while also providing the scientific and regulatory foundation for future STAb-T programs.

Contact Us

Write us an Email

info@stabtherapeutics.com

Twitter

Stay updated

LinkedIn

Follow us

Address

Calle Ferraz 78, 2º A, 28008 Madrid, Spain

 

© Copyright 2025 Stab Therapeutics – Web Design dspl.es

Scroll al inicio